10-K · March 26, 2026
Zentalis is a clinical‑stage oncology company focused on azenosertib (ZN‑c3), a WEE1 inhibitor prioritized toward registration in Cyclin E1‑positive platinum‑resistant ovarian cancer (PROC). The 10‑K highlights strong…
Earnings analysis · 10-Q
ZNTL earnings analysis
Filed May 12, 2026 · Our reading of the company's report
The latest report
Zentalis Pharmaceuticals reported its Q1 2026 results with a net loss of $35.4 million, resulting in an EPS of -$0.49, a slight beat on estimates of -$0.53. Revenue remains undisclosed, but cash reserves stand at $211.8…
Read full summary
Zentalis Pharmaceuticals reported its Q1 2026 results with a net loss of $35.4 million, resulting in an EPS of -$0.49, a slight beat on estimates of -$0.53. Revenue remains undisclosed, but cash reserves stand at $211.8 million, expected to fund operations into late 2027. The company faces ongoing challenges as clinical trials for its lead product, azenosertib, progress, amidst regulatory and competitive pressures.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.49
What stood out
-
Narrow EPS Loss Compared to Estimates
Diluted EPS was reported at -$0.49, better than the estimated -$0.53.
-
Strong Cash Position
Zentalis ended the quarter with $211.8 million in cash, expected to last into late 2027.
-
Decreased Operating Expenses
Total operating expenses fell significantly to $37.9 million from $45.6 million a year ago, mainly due to restructuring efforts.
-
Improved Clinical Trial Focus
Management emphasizes progress in DENALI and ASPENOVA trials for azenosertib as key drivers for future success.
-
No Revenue Generation
The company has not generated any revenue from product sales to date, continuing to rely on funding for operations.
-
Ongoing Regulatory Hurdles
Management expressed caution regarding the regulatory landscape affecting future commercialization efforts.
What to watch
-
Dependence on azenosertib
The company is heavily reliant on the success of azenosertib, which may face execution risks.
-
Significant Operating Losses
Zentalis reported a net loss of $35.4 million in Q1 2026, increasing operational financial strain.
-
Patent and Intellectual Property Risks
Litigation or challenges to Zentalis' intellectual property could adversely affect its product development capabilities.
Management's outlook
Management expects cash reserves to support operations into late 2027.
Earlier filings 4
10-Q · August 6, 2025
Zentalis reported no revenue for the three months ended June 30, 2025 and delivered an improved net loss per share of $(0.37) versus $(1.24) in Q2 2024, driven by materially lower operating expenses and a positive swing…
10-K · March 26, 2025
Zentalis is a clinical‑stage biotech focused on azenosertib (ZN-c3), a WEE1 inhibitor, and is prioritizing rapid development in Cyclin E1+ platinum‑resistant ovarian cancer (PROC). The company reported meaningful…
10-Q · November 12, 2024
Zentalis reported a third-quarter net loss of $40,158,000 (GAAP diluted loss per share $0.56) with no license revenue in the quarter. Net loss and EPS improved versus the year‑ago quarter (Q3 2023 net loss $55,540,000;…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.